ArticleCancer communications (London, England)2026
CAPTYN, a Blood-Based Machine-Learning Model Predicting Clinical Benefit of Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: Validation in the IMbrave150 Trial.
Gae Hoon Jo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.